What Is Nimesulide? Uses, Mechanism, and Liver Risks

Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) that preferentially blocks the COX-2 enzyme, giving it strong anti-inflammatory and painkilling effects with a somewhat gentler profile on the stomach than older NSAIDs. It is widely prescribed in parts of Europe, Asia, and Latin America for conditions like osteoarthritis, acute pain, and fever, yet it remains absent from the shelves in the United States, Canada, the United Kingdom, and several other countries. The reason for that split comes down to one organ: the liver. Nimesulide’s unusual mix of genuine clinical advantages and a small but real hepatotoxicity signal has made it one of the most debated painkillers in modern pharmacology.

How Nimesulide Works

Most traditional NSAIDs block both COX-1 and COX-2 enzymes more or less equally. COX-1 helps maintain the stomach lining and supports kidney blood flow, while COX-2 ramps up during inflammation and drives pain signaling. Nimesulide tips the balance heavily toward COX-2. In laboratory studies across more than ten research groups, it showed anywhere from about 1.3 to over 2,500 times greater selectivity for COX-2 than for COX-1, depending on the test system used. In a human volunteer study, two weeks of nimesulide at standard doses significantly reduced COX-2-driven prostaglandin production without touching COX-1 activity, while aspirin did essentially the opposite: it wiped out COX-1 activity with no meaningful effect on COX-2.¹

COX-2 selectivity alone does not fully explain nimesulide’s clinical effects, though. The drug also works through several COX-independent pathways. It inhibits the release of tumor necrosis factor alpha (TNF-α), a key driver of chronic inflammation. It tamps down histamine release, reduces the production of reactive oxygen species that damage tissue, and protects cartilage cells from dying off.² That cartilage-protective effect has made it particularly popular for osteoarthritis. In a head-to-head randomized trial against celecoxib and rofecoxib (two other COX-2-selective drugs), nimesulide provided significantly better symptomatic relief and faster pain reduction during walking.³

The Liver Controversy

Nimesulide’s central problem is hepatotoxicity. The absolute risk is low for any individual patient, but it is consistently higher than the background rate seen with other NSAIDs. A systematic review and meta-analysis pooling five observational studies found nimesulide roughly doubled the risk of liver injury compared to other NSAIDs. When the researchers looked at spontaneous adverse-event databases, the signal was even stronger: reported liver toxicity was about four times higher in nimesulide users than in users of other NSAIDs.⁴

An Italian case-control study added important nuance. Duration and dose both mattered: using nimesulide for more than 30 days carried a dramatically higher risk than short courses, and higher-than-recommended doses multiplied the danger further still.⁵ A large cohort study from a general-practice database confirmed the picture: the risk of liver injury with nimesulide was roughly double that of past NSAID use, and the increase grew more pronounced when researchers narrowed the definition to severe diagnoses.⁶

These findings are why the European Medicines Agency eventually restricted nimesulide to a maximum treatment duration of 15 days at the lowest effective dose. Several countries went further and pulled the drug from the market entirely. In nations where it remains available, a survey across nine European countries found that when doctors followed those prescribing restrictions, no critical safety issues surfaced in recent years, and periodic safety reviews were extended from every six months to every three years.⁷ So the practical takeaway is straightforward: nimesulide at standard doses for short stretches behaves like a reasonably safe NSAID; long courses or high doses raise the liver risk to a level most regulators find unacceptable.

What Happens Inside the Liver

Researchers have identified several overlapping mechanisms behind nimesulide’s liver toxicity, and they mostly converge on mitochondria. In isolated rat liver mitochondria, nimesulide acts as a potent uncoupler at concentrations that can realistically be reached in a living patient. It disrupts the normal flow of electrons through mitochondria, drains the cell’s reserves of key protective molecules like glutathione and NADPH, and forces calcium out of its usual compartments, triggering a process called mitochondrial permeability transition that can lead to cell death.⁸ A separate study measured about a 60 percent depletion of glutathione and a 75 percent drop in mitochondrial electron activity at relevant concentrations.⁹

The downstream consequences include the release of proteins that trigger programmed cell death. In a rat study, nimesulide depolarized mitochondria and activated the caspase enzymes that execute apoptosis, along with increasing a marker of oxidative DNA damage.¹⁰

There is also a metabolic angle. In the body, nimesulide gets broken down into a metabolite called M1, which itself is stable enough. But certain liver enzymes, particularly CYP2C19 and CYP1A2, can further oxidize M1 into a highly reactive intermediate that binds to proteins and potentially damages liver cells.¹¹ This reactive-metabolite pathway may explain why nimesulide liver injury is idiosyncratic, meaning it strikes unpredictably in a small number of people rather than following a straightforward dose-response pattern in everyone.

Why Some People Are More Vulnerable

The idiosyncratic nature of nimesulide hepatotoxicity has pushed researchers to look for genetic risk factors. One telling experiment used mice with only one working copy of the gene for mitochondrial superoxide dismutase (SOD2), an enzyme that neutralizes a particularly destructive form of free radical inside mitochondria. In these genetically vulnerable mice, nimesulide caused significant mitochondrial oxidative injury, increased markers of protein damage, and triggered liver cell death via apoptosis. In normal mice receiving the same dose, none of those effects appeared. Even in a test tube, nimesulide caused a concentration-dependent increase in superoxide only in mitochondria from the SOD2-deficient mice, leaving wild-type mitochondria unaffected.¹²

This matters because people vary in their mitochondrial antioxidant capacity. Someone whose genetic makeup or nutritional status leaves them with lower-than-average defenses against mitochondrial oxidative stress could be the person who develops liver trouble on nimesulide, while the vast majority of users clear the drug without incident. No commercial genetic test currently exists to flag this vulnerability before prescribing nimesulide, which is part of why regulators in more cautious markets have kept the drug off the formulary altogether rather than try to identify at-risk patients.

The Stomach Advantage

If nimesulide carries a higher liver risk, the natural question is why it has not simply been replaced everywhere by other NSAIDs. A large part of the answer is its gastrointestinal profile. Traditional NSAIDs are notorious for causing stomach ulcers, bleeding, and intestinal inflammation, and for patients with chronic pain conditions, that risk adds up over time. Nimesulide consistently performs better on this front. A systematic review of its use in older adults reported that it was better tolerated in the GI tract than diclofenac and at least comparable to naproxen and ibuprofen, with some evidence suggesting fewer toxicities overall.¹³

The mechanism behind this goes beyond just COX-2 selectivity. Conventional acidic NSAIDs directly increase the permeability of the small intestine, probably through a prostaglandin-independent mechanism. Nimesulide, because it is a very weakly acidic molecule, does not seem to do this.¹⁴ In head-to-head endoscopic comparisons with naproxen, nimesulide caused significantly less gastric and duodenal injury. Naproxen also boosted calprotectin, a marker of intestinal inflammation, while nimesulide had no measurable effect on it.¹⁵ For a patient whose biggest concern is GI bleeding rather than liver function, nimesulide has a real edge.

Heart and Kidney Risks

No NSAID gets a free pass on cardiovascular and kidney safety, and nimesulide is no exception. A large nested case-control study across four European countries found that nimesulide was among the NSAIDs associated with an increased risk of hospital admission for heart failure, alongside diclofenac, ibuprofen, naproxen, and the COX-2 inhibitors etoricoxib and rofecoxib.¹⁶ A study looking specifically at elderly people with diabetes found that nimesulide increased the risk of gastrointestinal bleeding relative to celecoxib, while ketorolac carried the greater cardiovascular hazard in that population.¹⁷

On the kidney side, nimesulide behaves much like other NSAIDs. In subjects also taking the diuretic furosemide, nimesulide caused a brief dip in kidney blood flow, blunted the diuretic’s ability to clear sodium and potassium, and sharply reduced urinary prostaglandin E2. The changes were transient in people with normal kidneys, but the researchers flagged them as potentially dangerous in anyone with pre-existing kidney problems.¹⁸ A review of 120 adverse event reports associated with nimesulide found 11 suspected renal reactions, most after short courses, and over half of those patients had other risk factors for kidney injury.¹⁹

Drug Interactions

Nimesulide interacts with several common medications in ways that matter clinically. It is heavily protein-bound in the bloodstream, which means it can jostle other protein-bound drugs off their binding sites. Fenofibrate, salicylic acid, and tolbutamide can all displace nimesulide, and nimesulide can in turn displace salicylic acid and furosemide. Warfarin is a notable exception: nimesulide does not usually displace it, and formal studies have mostly shown no change in anticoagulant effect. Still, a few patients have shown increased anticoagulant activity, so monitoring makes sense when the two drugs are combined.²⁰

Nimesulide may also reduce the oral bioavailability of furosemide and blunt its diuretic effect through the prostaglandin-dependent kidney mechanisms described above. Despite early concerns about interaction with the diabetes drug glibenclamide, formal testing found no influence on fasting blood sugar or glucose tolerance in diabetic patients on sulfonylureas. A small effect on theophylline levels has been noted, but it does not appear to change lung function tests in meaningful ways.

Pregnancy and Children

Nimesulide is contraindicated in the third trimester of pregnancy, and the case reports make clear why. Like all NSAIDs that block prostaglandin synthesis, it can cause premature constriction of the ductus arteriosus, a blood vessel in the fetal heart that needs to stay open until birth. A case report documented severe ductal constriction in a near-term fetus after the mother took just one or two oral doses of nimesulide as self-medication.²¹ Separate case reports have linked maternal nimesulide use to transient neonatal kidney failure, though disentangling it from other medications taken during pregnancy is difficult.²²

A randomized trial comparing nimesulide, indomethacin, and sulindac for preterm labor treatment found that all three caused similar short-term effects on the fetus, including ductal constriction and reduced amniotic fluid, but those effects resolved within 72 hours of stopping the drug. Nimesulide had no advantage over the other NSAIDs in terms of fetal side effects during short-term use for tocolysis.²³

In children, a systematic review of randomized controlled trials found that oral nimesulide was about as safe as other analgesics and fever reducers for short courses of ten days or fewer. The reviewers recommended avoiding it in children with known or suspected liver disease and flagged the lack of data for infants younger than six months.²⁴ Some countries have banned nimesulide in children entirely after reports of fatal hepatotoxicity in pediatric patients, though the evidence base is dominated by case reports rather than large-scale studies.

Topical Nimesulide Gel

One way to get nimesulide’s painkilling benefits while largely sidestepping its systemic risks is through topical gel formulations. These are applied directly to the skin over a sore joint or muscle. A pharmacokinetic comparison of three commercially available nimesulide gels found meaningful differences in how much drug actually crossed the skin barrier, so not all gel products are equivalent in practice.²⁵

In a double-blind trial comparing topical nimesulide gel to topical diclofenac, topical piroxicam, and placebo in healthy volunteers, nimesulide showed better analgesic efficacy and a faster onset of action, with peak pain relief around two hours after application. That time course tracked well with the drug’s absorption profile through the skin.²⁶ Topical use delivers far lower systemic blood levels than oral dosing, which in theory should drastically reduce the liver and kidney exposure that drives the serious adverse effects. For localized musculoskeletal pain, the gel represents a genuinely different risk-benefit calculation.

Environmental Footprint

Nimesulide does not vanish after it leaves the body. Like many pharmaceuticals, it ends up in wastewater and eventually in rivers and streams. Toxicology testing using zebrafish embryos found that nimesulide caused a range of developmental abnormalities at environmentally plausible concentrations, including spinal cord defects, pericardial swelling, and a roughly 30 percent drop in heartbeat rate. The calculated concentration lethal to half the embryos was under 1 microgram per milliliter.²⁷

A more recent study exposed adult zebrafish to nimesulide at concentrations actually detected in waterways and found that the drug reduced locomotion by about 30 percent, caused anxiety-like behavior, increased markers of oxidative tissue damage, and inhibited acetylcholinesterase activity in the brain. When combined with the antibiotic azithromycin, the effects compounded.²⁸ These findings do not directly threaten human health at current exposure levels, but they flag nimesulide as one of the pharmaceutical pollutants worth monitoring as drug residues in water systems accumulate. Proper disposal of unused medication, rather than flushing it, is a small step that applies to nimesulide just as it does to any other drug.